Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks
Crossref DOI link: https://doi.org/10.29328/journal.apps.1001055
Published Online: 2024-05-02
Update policy: https://doi.org/10.29328/crossmark-policy
Fonseca, Pandora Eloa Oliveira
Azevedo, Jeremias Aguiar
Bié, Sara Maria Gomes
Ferreira, Sávio Benvindo
License valid from 2024-05-02
